Literature DB >> 24346155

High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period.

Honghua Ye1, Fuwei He, Xiaohong Fei, Yanru Lou, Shiqi Wang, Rui Yang, Yewen Hu, Xiaomin Chen.   

Abstract

OBJECTIVE: We investigated atorvastatin reloading effects on endothelial progenitor cell (EPC) count and inflammatory cytokine expression after percutaneous coronary intervention (PCI) in patients with stable angina pectoris who had previously received long-term statin treatments.
METHODS: Patients with stable angina pectoris were treated with 80 mg atorvastatin 12 hours and 40 mg atorvastatin 2 hours before coronary angioplasty (n = 15) or preoperatively with 40 mg/d atorvastatin for 7 days (n = 15) or did not receive atorvastatin (n = 15). CD45-/133+/34+, CD45-/CD34+/kinase insert domain receptor (KDR)+, and CD45-/CD144+/KDR+ EPCs in the peripheral blood were determined by flow cytometry 1 hour before as well as 1 hour, 6 hours, and 24 hours after PCI. Soluble intercellular adhesion molecule 1 (sICAM-1), hypersensitive C-reactive protein (hCRP), and troponin-I (TnI) serum concentrations were analyzed immediately prior to and 24 hours after PCI.
RESULTS: In the 40mg Atorvastatin and control groups, none of the analyzed EPC blood concentrations changed significantly from 1h before operation to 1h and 6 h postoperative values. In contrast, the number of circulating early differentiation stage EPCs CD45-/133+/34+ and CD45-/CD34+/ KDR+ raised significantly from 1 h preoperative values (57.3±9.3; 57.3 ± 10.7) to 1 h postoperative ((74.4 ± 11.4; 78.8 ± 16.2), (p < 0.05)) and 6 h postoperative ((93 ± 16.9; 99.7 ± 11.9), (p < 0.05)) concentrations after coronary angioplasty in the 80mg Atorvastatin medication patients. In the control group, the sICAM-1 (174.55 ± 38.91 vs 204.11 ± 58.24) and hCRP (1.89 ± 1.93 vs 9.0 ± 11.1) serum concentrations at 24 hours after PCI were significantly elevated (P < .05) compared to preoperative values, whereas the increases in the 2 groups treated with atorvastatin were not significant. In addition, the rise in serum TnI concentration level from pre- to postoperative in the 80-mg (0.02 ± 0.02 vs 0.09 ± 0.08) and the 40-mg (0.01 ± 0.03 vs 1.2 ± 2.59) reloading groups was less than that of the controls (0.01 ± 0.02 vs 1.75 ± 3.09) (p < 0.05).
CONCLUSION: Our results suggested that high-dose atorvastatin application before PCI triggered early EPC circulation. Furthermore, postoperative inflammatory cytokine sICAM-1 as well as hCRP serum levels were reduced, while postinterventional myocardial injury marker TnI elevations were inversely correlated with statin reloadings.

Entities:  

Keywords:  arthrosclerosis; endothelial progenitor cells; percutaneous coronary intervention

Mesh:

Substances:

Year:  2013        PMID: 24346155     DOI: 10.1177/1074248413513500

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  9 in total

1.  Endogenous PCSK9 may influence circulating CD45neg/CD34bright and CD45neg/CD34bright/CD146neg cells in patients with type 2 diabetes mellitus.

Authors:  Romina Tripaldi; Paola Lanuti; Paola Giustina Simeone; Rossella Liani; Giuseppina Bologna; Sonia Ciotti; Pasquale Simeone; Augusto Di Castelnuovo; Marco Marchisio; Francesco Cipollone; Francesca Santilli
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

Review 2.  Vascular Ageing and Exercise: Focus on Cellular Reparative Processes.

Authors:  Mark D Ross; Eva Malone; Geraint Florida-James
Journal:  Oxid Med Cell Longev       Date:  2015-12-01       Impact factor: 6.543

3.  Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.

Authors:  Zahra Sepehri; Mohammad Masoumi; Nazanin Ebrahimi; Zohre Kiani; Ali Akbar Nasiri; Farhad Kohan; Mahmood Sheikh Fathollahi; Mohammad Kazemi Arababadi; Gholamreza Asadikaram
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

Review 4.  Endothelial progenitor cells: Exploring the pleiotropic effects of statins.

Authors:  Kully Sandhu; Mamas Mamas; Robert Butler
Journal:  World J Cardiol       Date:  2017-01-26

5.  Porous Polylactide Film Plus Atorvastatin-Loaded Thermogel as an Efficient Device for Peritoneal Adhesion Prevention.

Authors:  Jiannan Li; Xiangru Feng; Jian Shi; Tongjun Liu; Jianxun Ding
Journal:  ACS Omega       Date:  2018-03-07

Review 6.  The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair.

Authors:  Velimir Altabas; Lora Stanka Kirigin Biloš
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

7.  Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Heerajnarain Bulluck; Valeria Paradies; Emanuele Barbato; Andreas Baumbach; Hans Erik Bøtker; Davide Capodanno; Raffaele De Caterina; Claudio Cavallini; Sean M Davidson; Dmitriy N Feldman; Péter Ferdinandy; Sebastiano Gili; Mariann Gyöngyösi; Vijay Kunadian; Sze-Yuan Ooi; Rosalinda Madonna; Michael Marber; Roxana Mehran; Gjin Ndrepepa; Cinzia Perrino; Stefanie Schüpke; Johanne Silvain; Joost P G Sluijter; Giuseppe Tarantini; Gabor G Toth; Linda W Van Laake; Clemens von Birgelen; Michel Zeitouni; Allan S Jaffe; Kristian Thygesen; Derek J Hausenloy
Journal:  Eur Heart J       Date:  2021-07-15       Impact factor: 29.983

8.  The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD.

Authors:  Jonathan Watt; Simon Kennedy; Nadeem Ahmed; James Hayhurst; John D McClure; Colin Berry; Roger M Wadsworth; Keith G Oldroyd
Journal:  Open Heart       Date:  2016-01-28

9.  Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial.

Authors:  HamidReza Pourhosseini; Reza Lashkari; Arya Aminorroaya; Danesh Soltani; Arash Jalali; Masih Tajdini
Journal:  Int J Cardiol Heart Vasc       Date:  2019-01-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.